Skip to content

Clinical cohort study of endolymphatic sac decompression and chemical labyrinthectomy for refractory Meniere's disease

Endolymphatic sac decompression and chemical labyrinthectomy in refractory Meniere's disease: A clinical cohort study - Endolymphatic sac decompression and chemical labyrinthectomy in refractory Meniere's disease: A clinical cohort study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070187
Enrollment
Unknown
Registered
2023-04-04
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory MéNIèRE's disease

Interventions

Test Group:Endolymphatic sac decompression:None
Control Group:Chemical Labyrinthectomy (gentamicin tympanic injection):None

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Unilateral MESNIèRE's disease was definitely diagnosed and other intracranial and extracranial diseases were excluded; (2) Regular drug treatment for at least 3 months, during the course of treatment, frequent seizures, severe symptoms and Drug Treatment Difficult to control; (3) The hearing loss of the affected ear was between 40 and 60 dB, the hearing of the contralateral ear was normal; (4) The patients were willing to follow up.

Exclusion criteria

Exclusion criteria: (1) bilateral MESNIèRE's disease; (2) elderly patients over 70 years of age; (3) patients with external auditory canal infections; (4) women who are pregnant or preparing for pregnancy within 12 months; (5) patients with severe chronic disease that is not under control.

Design outcomes

Primary

MeasureTime frame
Frequency of Vertigo attacks;

Secondary

MeasureTime frame
dizziness handicap inventory ,DHI;Pure tone threshold;

Countries

China

Contacts

Public ContactHongsongDong

Shenzhen Second People's Hospital

donghs001@163.com+86 13556879681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026